This article is more than 5 years old. Information may no longer be current.
Othera, NEI reach target enrollment in trial of topical dry AMD drug
Click Here to Manage Email Alerts
EXTON, Pa. — A phase 2 clinical trial evaluating OT-551 as a topical treatment for geographic atrophy associated with age-related macular degeneration has reached its enrollment target, according to a press release from Othera Pharmaceuticals, the drug's developer.
The study is sponsored by the National Eye Institute and is being conducted at the National Institutes of Health Medical Center in Bethesda, Md. Investigators have enrolled 10 patients with bilateral geographic atrophy who will be treated with OT-551 in one eye three times per day for 24 months. The study is evaluating the potential for OT-551 to reduce the loss of central visual acuity and slow the enlargement of the atrophic area of the macula, according to the release.
OT-551 is currently in mid-stage phase 2 clinical development for treating both dry and wet forms of AMD as well as for preventing cataract development.
The drug acts through multiple pathways to down-regulate the disease-induced overexpression of nuclear factor kappa beta and reduce oxidative stress, according to the release.